
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is a biotechnology company focused on eye-care products in the US market, with a promising future of revenue growth through future product launches and strategic changes to address current challenges. Despite a decrease in Q1 revenue due to high deductible plans, the company remains confident in their 2026 revenue guidance and has implemented a new sales force to target even more markets for their underutilized products. With successful identification and utilization of underutilized drugs and the launch of new products like MELT, Harrow's stock has a positive outlook for potential growth in the coming years.
Bears say
Harrow is currently facing challenges with the performance of its product, Vevye, due to seasonality in the industry and a decrease in demand for high deductible health plans. This has led to a decrease in revenue and could impact the success of new product acquisitions.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares